von Tobias Borgers | März 21, 2024 | Bayer
Bayer has announced a licensing agreement with BridgeBio Pharma to commercialise acoramidis as a treatment for patients living with transthyretin amyloid cardiomyopathy (ATTR-CM). As part of the deal, Bayer will receive an exclusive license to commercialise acoramidis...
von Tobias Borgers | Feb. 2, 2024 | Bayer
NAIROBI (Reuters) – Germany’s Bayer will contract a third party to distribute its pharmaceutical products in four African markets including Kenya, it said, adding that the impact on jobs will be minimal. The company, which has 200 employees in the region,...
von Tobias Borgers | Jan. 19, 2024 | Bayer
Sun Pharmaceutical Industries Limited and Bayer on Thursday announced that both companies have signed an agreement to market and distribute a second brand of Finerenone in India. According to the company’s press statement, Finerenone, a patented medicine is indicated...
von Tobias Borgers | Mai 11, 2023 | Bayer
Yvonne Hao, Massachusetts’ secretary of economic development, speaks Thursday at the launch of Co.Lab in Cambridge’s Inman Square. (Photo: Office of Senator Sal DiDomenico) Bayer, the German pharmaceutical and biotech giant, launched Cambridge’s latest life-sciences...
von Tobias Borgers | Apr. 10, 2023 | Bayer
Pharma-Chef kritisiert Regulationswut: „In Deutschland fehlt der Zugang zu Forschungsdaten“ Der Pharma-Chef von Bayer, Stefan Oelrich, sieht Deutschland forschungspolitisch auf einem gefährlichen Weg. Noch habe er Hoffnung, sagte Oelrich im Tagesspiegel-Interview ,...
